Feasibility of catheter-based endovascular left ventricular reconstruction for heart failure with Bioventrix micro-anchor technology

4 December 2015

First implantation successfully completed by Prof. Louis Labrousse at Hôpital Haut-Lévèque in Bordeaux-Pessac France

Feasibility of catheter-based endovascular left ventricular reconstruction for heart failure with Bioventrix micro-anchor technology

San Ramon, California, and Bordeaux, France, - BioVentrix Inc., a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), announced today that it has achieved the first ever implantation of its micro-anchor technology from entirely within the left ventricle using a catheter-based endovascular approach. This milestone was realized in collaboration with Prof. Louis Labrousse, Chief of Cardiovascular Surgery at the world renowned Hôpital Haut-Lévèque in Bordeaux-Pessac France.

The pre-clinical study was performed in a previously infarcted ovine model which replicates the scar tissue and anatomy observed in human subjects following a myocardial infarction. The new technology proved it is feasible to identify post-ischemic scar tissue, access the scar from within the vasculature, and deploy Revivent micro-anchors to exclude the diseased tissue without opening the chest. 

BioVentrix has shown that the exclusion of scar tissue from the LV cavity in patients suffering from ischemic 
cardiomyopathy heart failure results in substantial improvements in Quality of Life. This study demonstrates the ability to accomplish the same outcomes with the current hybrid approach. The company anticipates this next generation system will be utilized in clinical trials in early 2016.

Click to read the full press release and learn more about the Revivent System and the LIVE Procedure  : www.bioventrix.com/press_release

« Go back